docetaxel + capecitabine or paclitaxel + gemcitabine or capecitabine + vinorelbine

This entry refers to a set of combination chemotherapy regimens used primarily in the treatment of advanced or metastatic cancers, especially breast and pancreatic cancer. Each regimen consists of two cytotoxic agents with distinct but complementary mechanisms: **docetaxel + capecitabine:** Docetaxel is a taxane that stabilizes microtubules, inhibiting cell division. Capecitabine is an oral prodrug converted to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts DNA synthesis. This combination has demonstrated superior efficacy over single-agent docetaxel in anthracycline-pretreated metastatic breast cancer, improving time to progression and overall survival[1][2][5]. **paclitaxel + gemcitabine:** Paclitaxel (including its albumin-bound form, nab-paclitaxel) is another taxane that disrupts microtubule function. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA strands and blocking replication. The combination—especially nab-paclitaxel plus gemcitabine—is approved for metastatic pancreatic cancer and improves survival compared to gemcitabine alone[6][7][8]. **capecitabine + vinorelbine:** Capecitabine acts as described above; vinorelbine is a vinca alkaloid that inhibits microtubule assembly, also disrupting mitosis. These regimens are administered intravenously (except for oral capecitabine) in cycles determined by the specific protocol for each disease setting.

Brand names

Taxotere + XelodaAbraxane + Gemzar

Other names

XT (for docetaxel/capecitabine)nab-paclitaxel/gemcitabine (for albumin-bound paclitaxel/gemcitabine)